



Biotech Daily

Wednesday June 13, 2012

Daily news on ASX-listed biotechnology companies

- * **ASX, BIOTECH DOWN: ANTISENSE UP 12%; GENETIC TECH DOWN 12.5%**
- * **GOVERNOR CHERNOV TO LEAD VICTORIA US BIO DELEGATION**
- * **BIOXYNE REQUESTS HI-164OV PHASE IIb RESULTS TRADING HALT**
- * **CHALLENGER, NOVAPORT BELOW 5% IN MEDICAL DEVELOPMENTS**

MARKET REPORT

The Australian stock market fell 0.22 percent on Wednesday June 13, 2012 with the S&P ASX 200 down 9.1 points to 4,063.8 points.

Twelve of the Biotech Daily Top 40 stocks were up, 14 fell, eight traded unchanged and six were untraded.

Antisense was the best, up 0.2 cents or 11.8 percent to 1.9 cents with 35.2 million shares traded.

Prima climbed 4.35 percent; Optiscan, Reva and Phosphagenics were up more than three percent; Impedimed was up 3.45 percent; Starpharma and Tissue Therapies rose more than two percent; Alchemia, Bionomics and Resmed were up more than one percent; with Heartware, QRX and Sirtex up by less than one percent.

Genetic Technologies led the falls, down 1.5 cents or 12.5 percent to 10.5 cents, with 361,614 shares traded.

Anteo lost 5.9 percent; Neuren fell four percent; Mesoblast, Prana and Viralytics were down more than three percent; Pharmaxis and Phylogica shed more than two percent; Bioniche, Circadian and Clinuvel were down more than one percent; with Acrux, Cochlear, CSL, Nanosonics and Psivida down by less than one percent.

VICTORIA GOVERNMENT

The Victoria Governor Alex Chernov will lead the Victorian delegation to Boston for the Biotechnology Industry Organization 2012 annual conference, June 18-21, 2012.

Victoria's Technology Minister Gordon Rich-Phillips said that Mr Chernov would lead the delegation of about 60 representatives from Victoria's biotechnology industry.

"Victoria's biotechnology industry is growing at a rapid rate, with total market capitalization of Victoria's life sciences tripling to \$24 billion in the past 10 years," Mr Rich-Phillips said.

"The BIO 2012 mission offers a great opportunity to raise the profile of Victoria as a leading Asia-Pacific centre for biotechnology and innovation and to grow Victorian partnerships, investments, jobs and exports," Mr Rich-Phillips said.

"BIO attracts the biggest names in biotechnology, offers strategic networking and investment partnering opportunities and provides insight into the major trends in the industry," Mr Rich-Phillips said.

"We are home to a growing pharmaceuticals manufacturing base and our expertise in stem cell, infectious disease, cancer, neuroscience and agricultural biotechnology is internationally recognized," Mr Rich-Phillips said.

Mr Rich-Phillips said that Victoria's \$55 million plan to support technology-enabled innovation and stimulate productivity growth included funds for Victorian companies and organizations to attend overseas events and missions, such as BIO.

The Victoria Government said that Governor Chernov would address the Australian Biotechnology Investment Showcase in New York on June 15, 2012.

BIOXYNE (FORMERLY HUNTER IMMUNOLOGY)

Bioxyne has requested a trading halt pending the results of its phase IIb trial of HI-164OV immunotherapy for chronic obstructive pulmonary disease (COPD).

Bioxyne said the results would be an extensive review of both primary and secondary results which required significant interpretation and an incorrect interpretation could result in a significant share price movement both positive and negative.

Trading will resume on June 15, 2012 or on an earlier announcement.

Bioxyne last traded at 24 cents.

MEDICAL DEVELOPMENTS INTERNATIONAL

Challenger and Novaport Capital have ceased their substantial shareholding in Medical Developments from 2,859,870 shares (5.14%) to 2,756,103 shares (4.95%).

The companies said they sold the 103,767 shares for \$82,050 or an average price of 79.1 cents a share.

Last week Challenger and Novaport reduced their holding in Medical Developments from 3,306,103 shares (6.14%) to 2,859,870 shares (5.14%) at an average price of 64.2 cents a share (BD: Jun 5, 2012).

In 2011, Novaport said it acquired 4,769,957 shares for \$1,860,283 or 39 cents a share and in February this year sold 400,000 shares for \$218,997 or an average price of 54.7 cents each (BD: Jan 31, 2011; Feb 27, 2012).

Medical Developments was up one cent or 1.3 percent to 75.5 cents.